Amplia Therapeutics has signed a collaboration agreement with Eli Lilly to evaluate a combination of Amplia’s investigational FAK inhibitor, narmafotinib, with Lilly’s KRAS G12C inhibitor, olomorasib, in a Phase 1b/2b trial for advanced non-small cell lung cancer (NSCLC). This study aims to improve treatment outcomes by addressing resistance to KRAS inhibitors, expanding Amplia’s clinical reach beyond pancreatic and ovarian cancers. The trial is set to start in late 2026 in Australia and the USA, leveraging Lilly’s drug supply to efficiently explore this promising combination therapy in a large market valued at over $31 billion.
Amplia Therapeutics has entered a clinical collaboration with Eli Lilly to test their drug narmafotinib combined with Lilly's KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer (NSCLC) patients. The Phase 1b/2b trial will evaluate ...
Wall Street is expected to start August mostly higher with Dow Jones futures up 1% and S&P 500 gaining 0.5%, while Nasdaq futures remain flat following a recent tech rebound. Last month, technology stocks struggled, notably the Philadelphia Semicondu...
Eli Lilly's investigational drug olomorasib received FDA Breakthrough Therapy designation for treating advanced pancreatic cancer patients with the KRAS G12C mutation who have had prior systemic therapy. This designation aims to speed up development ...
SpaceX will release its first public earnings report focusing on Starlink's growth, Starship development, and capital spending. Despite shares falling over 50% from their peak and trading below the IPO price, Wall Street remains optimistic with bulli...
As employers increasingly drop insurance coverage for GLP-1 weight-loss drugs like Wegovy and Zepbound, major retailers such as Walmart, Costco, CVS, and Amazon are expanding direct-to-consumer prescription programs to capture market share. These pro...
